Cas:855239-61-1 1,3,5-tris(3-iodophenyl)benzene manufacturer & supplier

Chemical Name:1,3,5-tris(3-iodophenyl)benzene

CAS.NO:855239-61-1

Synonyms:3,3”-Diiodo-5′-(3-iodophenyl)-1,1′:3′,1”-terphenyl

Molecular Formula:C₂₄H₁₅I₃

Molecular Weight:684.08900

HS Code:2903999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:683.83100

LogP:8.50140

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3,3”-Diiodo-5′-(3-iodophenyl)-1,1′:3′,1”-terphenyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,3”-Diiodo-5′-(3-iodophenyl)-1,1′:3′,1”-terphenyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,3”-Diiodo-5′-(3-iodophenyl)-1,1′:3′,1”-terphenyl Use and application,3,3”-Diiodo-5′-(3-iodophenyl)-1,1′:3′,1”-terphenyl technical grade,usp/ep/jp grade.

Related News: That impacts airlines’ business, making it less financially attractive for them to fly those routes to China. 1,3,5-tris(3-iodophenyl)benzene manufacturer ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety. 1,3,5-tris(3-iodophenyl)benzene supplier ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety. 1,3,5-tris(3-iodophenyl)benzene vendor There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association. 1,3,5-tris(3-iodophenyl)benzene factory There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association.